Shared Research logo
  • Home
  • All Companies
    All Companies
    Companies
    Recently viewed
    Browse companies...
  • English日本語
  • Log in
  • Sign up
Overview
My Comments
My Notes
SymBio Pharmaceuticals

SymBio Pharmaceuticals 4582

シンバイオ製薬
SymBio Pharmaceuticals Limited
Recent Updates
2022-06-15
Submission of clinical trial notification for global phase II study of BCV IV targeting BK virus infection in kidney transplant recipients
2022-06-03
Q1 FY12/22 report update
2022-05-18
Announcement concerning the license agreement with Chimerix for brincidofovir
Get in touch
Toranomon 30 Mori Building 3-2-2 Toranomon, Minato-ku Tokyo, JAPAN 105-0001
http://www.symbiopharma.com/index.html
Summary
SymBio is a specialty pharmaceutical company that buys the right to develop and commercialize drug candidates in order to address the underserved medical needs of patients in Japan and the rest of Asia. With its main focus on the areas of oncology, hematology, and pain management, the company typically seeks in-licensing opportunities for niche markets from pharmaceutical and biotech companies based in the US or EU.
Pharmaceuticals
Key dates
2014-10-31
Coverage initiation